PAVM - PAVmed-Lucid esophageal precancer detection test in DOD funded study

Lucid Diagnostics (NASDAQ:LUCD), majority-owned unit of PAVmed (NASDAQ:PAVM), said the first patient was enrolled in a Department of Defense funded study of its EsoGuard Esophageal DNA Test in at-risk patients with gastroesophageal reflux disease (GERD). The study is being carried out by investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center. The study will enroll up to 100 Cleveland VA patients. Lucid is providing EsoCheck Esophageal Cell Collection Devices for the study and will perform EsoGuard testing on the samples collected. “The study will add important clinical evidence on the impact of EsoGuard in enhancing early detection of esophageal precancer to prevent esophageal cancer deaths by reserving endoscopy for those with a positive EsoGuard test," said Lucid’s Chairman and CEO Lishan Aklog.

For further details see:

PAVmed-Lucid esophageal precancer detection test in DOD funded study